Literature DB >> 12660950

Immunogenic protein contaminants in pneumococcal vaccines.

Jigui Yu1, David E Briles, Janet A Englund, Susan K Hollingshead, W Paul Glezen, Moon H Nahm.   

Abstract

Currently available pneumococcal vaccines were examined for contamination by pneumococcal surface protein A (PspA) and pneumococcal surface adhesin A (PsaA). PspA could be detected in some (but not all) lots of 23-valent polysaccharide vaccine. Many lots of pneumococcal vaccines, including the heptavalent conjugate vaccine, were found to elicit small (but variable) antibody responses to PspA, PsaA, or both. The degree of contamination was highly variable, and this should be considered in pneumococcal vaccine evaluations or when capsular polysaccharide is used for pneumococcal antibody assays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660950     DOI: 10.1086/368200

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

2.  Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination.

Authors:  Mike Recher; Julia R Hirsiger; Marc B Bigler; Martin Iff; Barbara Lemaître; Kathrin Scherer; Peter Häusermann; Claire-Anne Siegrist; Christoph T Berger
Journal:  NPJ Vaccines       Date:  2018-05-18       Impact factor: 7.344

3.  Comparative Study of Immunogenic Properties of Purified Capsular Polysaccharides from Streptococcus suis Serotypes 3, 7, 8, and 9: the Serotype 3 Polysaccharide Induces an Opsonizing IgG Response.

Authors:  Guillaume Goyette-Desjardins; Jean-Philippe Auger; Dominic Dolbec; Evgeny Vinogradov; Masatoshi Okura; Daisuke Takamatsu; Marie-Rose Van Calsteren; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.